Nanoplatform-Mediated Autophagy Regulation and Combined Anti-Tumor Therapy for Resistant Tumors
Caixia Yang,Yuan Ding,Zhengwei Mao,Weilin Wang
DOI: https://doi.org/10.2147/ijn.s445578
IF: 7.033
2024-01-27
International Journal of Nanomedicine
Abstract:Caixia Yang, 1, 2, &ast Yuan Ding, 1, 2, &ast Zhengwei Mao, 3 Weilin Wang 1, 2 1 Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China; 2 Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China; 3 MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhengwei Mao, Department of Polymer Science and Engineering, Zhejiang University, No. 866 Yuhangtang Road, Hangzhou, Zhejiang, 310058, People's Republic of China, Tel +86057187783820, Fax +86057187068001, Email Weilin Wang, Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang, 310009, People's Republic of China, Email The overall cancer incidence and death toll have been increasing worldwide. However, the conventional therapies have some obvious limitations, such as non-specific targeting, systemic toxic effects, especially the multidrug resistance (MDR) of tumors, in which, autophagy plays a vital role. Therefore, there is an urgent need for new treatments to reduce adverse reactions, improve the treatment efficacy and expand their therapeutic indications more effectively and accurately. Combination therapy based on autophagy regulators is a very feasible and important method to overcome tumor resistance and sensitize anti-tumor drugs. However, the less improved efficacy, more systemic toxicity and other problems limit its clinical application. Nanotechnology provides a good way to overcome this limitation. Co-delivery of autophagy regulators combined with anti-tumor drugs through nanoplatforms provides a good therapeutic strategy for the treatment of tumors, especially drug-resistant tumors. Notably, the nanomaterials with autophagy regulatory properties have broad therapeutic prospects as carrier platforms, especially in adjuvant therapy. However, further research is still necessary to overcome the difficulties such as the safety, biocompatibility, and side effects of nanomedicine. In addition, clinical research is also indispensable to confirm its application in tumor treatment. Keywords: autophagy, tumor resistance, nanotechnology, combination therapy, co-delivery Cancer is a global public health problem, especially malignant tumors. According to the American Cancer Society, mortality of cancer has continued to decline by 29% since 1991. 1 However, cancer remains one of the leading causes of death in the world. With the combined effects of multiple factors such as the aging of the population, population growth, serious environmental pollution and bad living habits, the overall cancer incidence and death toll have been increasing worldwide. As of 2020, an estimated 19.3 million new cancer cases occurred. Notably, the global cancer burden is expected to increase by 47% compared to 2020. 2 The increasing burden of cancer has brought considerable difficulties and challenges to both health care system and social development. Anti-tumor therapy mainly involves surgical treatment, radiotherapy, gene therapy, and other types of treatments. In recent years, with the continuous breakthroughs in medical scientific research, the innovation of medical technology, there are several types of current anti-tumor drugs: 3 cytotoxic chemotherapy drugs, 4 cell differentiation inducers, 5 cell death inducers, antiangiogenic agents, 6 hormonal therapy drugs, 7 targeted therapy drugs, 8 immunotherapy drugs, 9 bacteria-based therapy drugs, 10,11 photodynamic therapy and photothermal drugs, 12 etc. Although the above conventional therapies have improved the survival rate of tumor patients to a certain extent, they also have obvious limitations, such as non-specific targeting, drug resistance, systemic toxic effects, adverse side effects and limited indications, 13 especially the multidrug resistance (MDR) of tumors, which is the main obstacle to tumor treatment, especially metastatic tumors. This MDR reaction not only causes poor anti- tumor efficacy, 14 but also is related to the recurrence and metastasis of cancer, 15 leading to treatment failure. 16 Tumors may develop multidrug resistance to anti-tumor therapy drugs through a variety of mechanisms: 1) changes in -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology